Oncology CRO services – Cell Line-derived Xenograft (CDX) Mouse Models
Cell-line derived xenograft (CDX) mouse models represent one of the first steps of determining the efficacy of your novel anticancer therapies in an in vivo model
InnoSer’s Cell Line-derived Xenograft (CDX) Mouse Models Services
Cell line-derived xenograft (CDX) mouse models are established from immortalized human cancer cells that are implanted and grown in immunodeficient mice. However, to fully recapitulate the intricacies between the immune system and the rodent tumor microenvironment, humanized models are recommended instead of immunodeficient mice. In comparison to syngeneic mouse models, human cell line-derived xenograft (CDX) models offer you the advantage of working with a mouse model with relevant human cancer target proteins as opposed to rodent proteins.
Therefore, experts at InnoSer recommend the use of CDX models as a first step to evaluate the efficacy of your novel targeted anti-cancer compounds using in vivo models of human cancer. Accordingly, cell line-derived xenograft (CDX) mouse models represent an easy-to-use and relatively inexpensive mouse model with short study timelines (2-4 weeks), offering you a cost-effective alternative to other preclinical screening models. However, for running more advanced studies, InnoSer’s experts recommend performing in vivo studies using patient-derived xenograft (PDX) mouse models, offering you the most clinically relevant in vivo cancer model.
✓ Available as subcutaneous, metastatic, or orthotopic models (follow-up can be also done via imaging methods such as ultrasound).
✓ Both murine and rat cell lines are available.
✓ Complementary biodistribution, microenvironment studies, and PK/PD profiling services.
Developing new, safe, and efficacious anticancer therapies is an extremely intricate process. As a preclinical oncology contract research organization (CRO), InnoSer partners with you to help you navigate the complexities of this research area.
Scientists at InnoSer collaborate with you to develop the most optimal study design to help answer your research questions in the most cost-effective way. With flexible and fast study start times you can perform your research at an accelerated pace. By outsourcing your preclinical oncology studies to InnoSer, you gain access to our in vitro and in vivo oncology drug development portfolio.
Unlock the Right Tools for Your Research.
Explore and compare our oncology platforms to identify the perfect model for your study needs.
Key Cell Line-derived Xenograft (CDX) Mouse Models Readouts
The People Behind Your Research
Céline Erens, PhD, Immunology Study Director
An expert team led by our immuno-oncology study director, Céline Erens helps you choose the right tools and set up optimal study designs. Curating the preclinical testing of your lead compounds with a deep understanding of the field is your solution to accelerating your drug development.
Yanick Fanton, PhD, Chief Scientific Officer
As Chief Science Officer at InnoSer, Yanick is responsible for all customer studies at InnoSer and takes care of the scientific and technical coordination.
Oncology Board Members
Prof. Dr. Esther Wolfs
A member of InnoSer’s Scientific Advisory Board, Dr. Wolfs is a leading researcher in stem cell therapy. Currently a professor at the University of Hasselt, Ester uses stem cells in anticancer therapy and as a model to study Charcot-Marie-Tooth disease type 1A.
MD, PhD Marije Slingerland
A member of InnoSer’s Scientific Advisory Board, Dr. Slingerland from Leiden University Medical Center focuses on clinical trials in gastrointestinal cancer and in head and neck cancer, particularly on intratumoral immune parameters.
Frequently Asked Questions
What is the difference between CDX and syngeneic mouse models?
Syngeneic mouse models are established by injecting rodent cell lines into recipient mice of the same genetic background from which the immortalized cells were derived. In contrast, cell line-derived (CDX) xenograft mouse models are established by injecting human-immortalized cancer cell lines into immunodeficient mice.
- Syngeneic mouse models have an intact immune system, making them highly suitable for testing therapies that rely on immune mechanisms, such as immune checkpoint inhibitors.
- In contrast, CDX models are ideal for studying human-specific tumor biology and assessing therapies that do not require an active immune system. Choosing the right model depends on the therapeutic mechanism of action, research objectives, and stage of development.
Discuss with our team to determine which model is best suited for your study.
What is the most suitable mouse and genetic backgrounds for CDX studies?
- Nude mice: The immunocompromised nude mice represent the ideal recipient mouse strain due to no rejection responses. Moreover, nude mice are preferred for studies involving bioluminescent imaging (BLI) and fluorescent imaging (FLI) due to the absence of fur, reducing signal interference. The absence of fur in nude mice may also additional make it easier to identify subcutaneous tumors.
- NSG (NOD scid gamma) mice: The highly immunodeficient NSG mice are suitable engraftment of human tumors as well as establishment of human immunity following hematopoietic stem cell transplantation.
- BRGSF mice: Compared to nude and NSG mice, BRGSF mice represent the most defective immunodeficient strain, suitable for xenografting of human tumors or transplantation of the human immune system due to the additional lack of functional dendritic cells.
Do you have a list of available CDX mouse models at InnoSer?
- Pancreatic cancer cell lines (asPC1, BXPC-3, MIA Paca-2, and Panc-1)
- Glioblastoma human cancer cell lines (U87, also luciferase-tagged for bioluminescence imaging [BLI] studies).
I don't see my cell line of interest in your CDX mouse model list, can InnoSer validate new models on request?
Yes, InnoSer can validate new CDX mouse models in close collaboration with clients. InnoSer has a strong track record of partnering with academic and industry clients to develop and test novel cancer cell lines. The validation process consists of determining the optimal cell inoculation density to achieve consistent, reproducible, and progressive tumor growth kinetics.
Discover Other Related Oncology Research Models
Stay Curious: More Articles to Explore
Multiplex Cytokine and Immune Cell Profiling in Immuno-Oncology Research
The Meso-Scale Discovery (MSD) platform is a high-sensitivity, multiplex cytokine profiling analysis system, enabling you to simultaneously quantify multiple target cytokines, chemokines, antibodies, and growth factors from minute sample volumes (as low as 1 µL). By...
Pancreatic Cancer PDX Models
Last month, November, represented Pancreatic Cancer Awareness Month; a time to focus on the challenges posed by one of the most aggressive and lethal cancer types. Pancreatic cancer accounts for approximately 3% of all diagnosed cancers in Europe, with pancreatic...
Exploring InnoSer’s Key In vitro Oncology Services: PD-1 PD-L1 Blockade Assay
Immune Checkpoint Blockade in Oncology Drug Discovery In recent years, immune checkpoint blockade has emerged as a groundbreaking therapeutic strategy in immuno-oncology. Programmed cell death 1 receptor (PD-1), and its ligand programmed cell death ligand 1 (PD-L1)...
RENCA Mouse Mouse Model of Renal Cancer
Approximately 400,000 people are diagnosed with kidney cancer annually. Kidney tumors are classified into different subtypes based on the cell of origin. Over 85% of malignant renal cell tumors are RCC, with the other 15% being nephroblastic, mesenchymal and...
AAALAC Accreditation
InnoSer has earned the AAALAC accreditation, demonstrating our commitment to responsible animal care and use. AAALAC International is a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. Our accreditation is valid for three years, incl. 2023. Read more about the AAALAC accreditation programme here.
Animal Welfare
The 3Rs impact everything from policy and regulatory change to the development and uptake of new technologies and approaches. This is why InnoSer has ongoing commitment and monitoring of these processes. The steps we practice maximize our ability to replace, reduce and refine animal involvement and facilitate our commitment to these principles when it comes to research and drug development.
info@innoserlaboratories.com